nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—ABCB1—esophageal cancer	0.436	1	CbGaD
Citalopram—Abdominal discomfort—Capecitabine—esophageal cancer	0.00039	0.00111	CcSEcCtD
Citalopram—Hepatic failure—Methotrexate—esophageal cancer	0.00039	0.00111	CcSEcCtD
Citalopram—Pancytopenia—Capecitabine—esophageal cancer	0.000386	0.0011	CcSEcCtD
Citalopram—Malnutrition—Cisplatin—esophageal cancer	0.000384	0.00109	CcSEcCtD
Citalopram—Erythema—Cisplatin—esophageal cancer	0.000384	0.00109	CcSEcCtD
Citalopram—Dysuria—Capecitabine—esophageal cancer	0.00038	0.00108	CcSEcCtD
Citalopram—Renal failure acute—Methotrexate—esophageal cancer	0.000379	0.00108	CcSEcCtD
Citalopram—Flatulence—Cisplatin—esophageal cancer	0.000379	0.00107	CcSEcCtD
Citalopram—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000378	0.00107	CcSEcCtD
Citalopram—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000371	0.00105	CcSEcCtD
Citalopram—Weight increased—Capecitabine—esophageal cancer	0.00037	0.00105	CcSEcCtD
Citalopram—Visual disturbance—Methotrexate—esophageal cancer	0.000369	0.00105	CcSEcCtD
Citalopram—Muscle spasms—Cisplatin—esophageal cancer	0.000369	0.00105	CcSEcCtD
Citalopram—Weight decreased—Capecitabine—esophageal cancer	0.000368	0.00104	CcSEcCtD
Citalopram—Hyperglycaemia—Capecitabine—esophageal cancer	0.000367	0.00104	CcSEcCtD
Citalopram—Pneumonia—Capecitabine—esophageal cancer	0.000365	0.00103	CcSEcCtD
Citalopram—Infestation NOS—Capecitabine—esophageal cancer	0.000362	0.00103	CcSEcCtD
Citalopram—Infestation—Capecitabine—esophageal cancer	0.000362	0.00103	CcSEcCtD
Citalopram—Vision blurred—Cisplatin—esophageal cancer	0.000362	0.00103	CcSEcCtD
Citalopram—Depression—Capecitabine—esophageal cancer	0.000361	0.00103	CcSEcCtD
Citalopram—Tremor—Cisplatin—esophageal cancer	0.00036	0.00102	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000359	0.00102	CcSEcCtD
Citalopram—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000357	0.00101	CcSEcCtD
Citalopram—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000357	0.00101	CcSEcCtD
Citalopram—Lethargy—Methotrexate—esophageal cancer	0.000357	0.00101	CcSEcCtD
Citalopram—Ill-defined disorder—Cisplatin—esophageal cancer	0.000356	0.00101	CcSEcCtD
Citalopram—Myocardial infarction—Capecitabine—esophageal cancer	0.000355	0.00101	CcSEcCtD
Citalopram—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000355	0.00101	CcSEcCtD
Citalopram—Anaemia—Cisplatin—esophageal cancer	0.000355	0.00101	CcSEcCtD
Citalopram—Stomatitis—Capecitabine—esophageal cancer	0.000353	0.001	CcSEcCtD
Citalopram—Jaundice—Capecitabine—esophageal cancer	0.000353	0.001	CcSEcCtD
Citalopram—Conjunctivitis—Capecitabine—esophageal cancer	0.000352	0.001	CcSEcCtD
Citalopram—Urinary tract infection—Capecitabine—esophageal cancer	0.000352	0.001	CcSEcCtD
Citalopram—Osteoarthritis—Methotrexate—esophageal cancer	0.00035	0.000994	CcSEcCtD
Citalopram—Malaise—Cisplatin—esophageal cancer	0.000346	0.000984	CcSEcCtD
Citalopram—Haematuria—Capecitabine—esophageal cancer	0.000346	0.000981	CcSEcCtD
Citalopram—Leukopenia—Cisplatin—esophageal cancer	0.000344	0.000976	CcSEcCtD
Citalopram—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000343	0.000973	CcSEcCtD
Citalopram—Epistaxis—Capecitabine—esophageal cancer	0.000342	0.000971	CcSEcCtD
Citalopram—Agranulocytosis—Capecitabine—esophageal cancer	0.000338	0.00096	CcSEcCtD
Citalopram—Irritability—Methotrexate—esophageal cancer	0.000334	0.000949	CcSEcCtD
Citalopram—Convulsion—Cisplatin—esophageal cancer	0.000333	0.000945	CcSEcCtD
Citalopram—Mood swings—Methotrexate—esophageal cancer	0.000332	0.000942	CcSEcCtD
Citalopram—Bradycardia—Capecitabine—esophageal cancer	0.000331	0.00094	CcSEcCtD
Citalopram—Ataxia—Methotrexate—esophageal cancer	0.000329	0.000935	CcSEcCtD
Citalopram—Myalgia—Cisplatin—esophageal cancer	0.000327	0.000929	CcSEcCtD
Citalopram—Haemoglobin—Capecitabine—esophageal cancer	0.000327	0.000928	CcSEcCtD
Citalopram—Rhinitis—Capecitabine—esophageal cancer	0.000326	0.000926	CcSEcCtD
Citalopram—Anxiety—Cisplatin—esophageal cancer	0.000326	0.000925	CcSEcCtD
Citalopram—Haemorrhage—Capecitabine—esophageal cancer	0.000325	0.000924	CcSEcCtD
Citalopram—Hepatitis—Capecitabine—esophageal cancer	0.000325	0.000924	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000325	0.000922	CcSEcCtD
Citalopram—Hypoaesthesia—Capecitabine—esophageal cancer	0.000324	0.000919	CcSEcCtD
Citalopram—Liver function test abnormal—Methotrexate—esophageal cancer	0.000323	0.000918	CcSEcCtD
Citalopram—Discomfort—Cisplatin—esophageal cancer	0.000323	0.000918	CcSEcCtD
Citalopram—Pharyngitis—Capecitabine—esophageal cancer	0.000323	0.000917	CcSEcCtD
Citalopram—Urinary tract disorder—Capecitabine—esophageal cancer	0.000321	0.000912	CcSEcCtD
Citalopram—Oedema peripheral—Capecitabine—esophageal cancer	0.00032	0.00091	CcSEcCtD
Citalopram—Connective tissue disorder—Capecitabine—esophageal cancer	0.00032	0.000908	CcSEcCtD
Citalopram—Urethral disorder—Capecitabine—esophageal cancer	0.000319	0.000905	CcSEcCtD
Citalopram—Breast disorder—Methotrexate—esophageal cancer	0.000316	0.000898	CcSEcCtD
Citalopram—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000315	0.000895	CcSEcCtD
Citalopram—Anaphylactic shock—Cisplatin—esophageal cancer	0.000314	0.00089	CcSEcCtD
Citalopram—Oedema—Cisplatin—esophageal cancer	0.000314	0.00089	CcSEcCtD
Citalopram—Visual impairment—Capecitabine—esophageal cancer	0.000314	0.00089	CcSEcCtD
Citalopram—Infection—Cisplatin—esophageal cancer	0.000312	0.000884	CcSEcCtD
Citalopram—Erythema multiforme—Capecitabine—esophageal cancer	0.000308	0.000873	CcSEcCtD
Citalopram—Nervous system disorder—Cisplatin—esophageal cancer	0.000307	0.000873	CcSEcCtD
Citalopram—Thrombocytopenia—Cisplatin—esophageal cancer	0.000307	0.000872	CcSEcCtD
Citalopram—Tachycardia—Cisplatin—esophageal cancer	0.000306	0.000869	CcSEcCtD
Citalopram—Skin disorder—Cisplatin—esophageal cancer	0.000305	0.000865	CcSEcCtD
Citalopram—Eye disorder—Capecitabine—esophageal cancer	0.000304	0.000863	CcSEcCtD
Citalopram—Tinnitus—Capecitabine—esophageal cancer	0.000303	0.000861	CcSEcCtD
Citalopram—Hyperhidrosis—Cisplatin—esophageal cancer	0.000303	0.000861	CcSEcCtD
Citalopram—Asthma—Methotrexate—esophageal cancer	0.000303	0.000859	CcSEcCtD
Citalopram—Cardiac disorder—Capecitabine—esophageal cancer	0.000302	0.000857	CcSEcCtD
Citalopram—Flushing—Capecitabine—esophageal cancer	0.000302	0.000857	CcSEcCtD
Citalopram—Eosinophilia—Methotrexate—esophageal cancer	0.0003	0.000851	CcSEcCtD
Citalopram—Anorexia—Cisplatin—esophageal cancer	0.000299	0.000849	CcSEcCtD
Citalopram—Pancreatitis—Methotrexate—esophageal cancer	0.000297	0.000842	CcSEcCtD
Citalopram—Angiopathy—Capecitabine—esophageal cancer	0.000295	0.000838	CcSEcCtD
Citalopram—Immune system disorder—Capecitabine—esophageal cancer	0.000294	0.000834	CcSEcCtD
Citalopram—Mediastinal disorder—Capecitabine—esophageal cancer	0.000293	0.000832	CcSEcCtD
Citalopram—Hypotension—Cisplatin—esophageal cancer	0.000293	0.000832	CcSEcCtD
Citalopram—Chills—Capecitabine—esophageal cancer	0.000292	0.000829	CcSEcCtD
Citalopram—Arrhythmia—Capecitabine—esophageal cancer	0.000291	0.000825	CcSEcCtD
Citalopram—Abdominal discomfort—Methotrexate—esophageal cancer	0.00029	0.000824	CcSEcCtD
Citalopram—Alopecia—Capecitabine—esophageal cancer	0.000287	0.000816	CcSEcCtD
Citalopram—Pancytopenia—Methotrexate—esophageal cancer	0.000287	0.000816	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000286	0.000811	CcSEcCtD
Citalopram—Mental disorder—Capecitabine—esophageal cancer	0.000285	0.000809	CcSEcCtD
Citalopram—Malnutrition—Capecitabine—esophageal cancer	0.000283	0.000804	CcSEcCtD
Citalopram—Erythema—Capecitabine—esophageal cancer	0.000283	0.000804	CcSEcCtD
Citalopram—Dysuria—Methotrexate—esophageal cancer	0.000283	0.000803	CcSEcCtD
Citalopram—Paraesthesia—Cisplatin—esophageal cancer	0.000282	0.000799	CcSEcCtD
Citalopram—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000281	0.000798	CcSEcCtD
Citalopram—Dyspnoea—Cisplatin—esophageal cancer	0.00028	0.000794	CcSEcCtD
Citalopram—Flatulence—Capecitabine—esophageal cancer	0.000279	0.000792	CcSEcCtD
Citalopram—Erectile dysfunction—Methotrexate—esophageal cancer	0.000279	0.000791	CcSEcCtD
Citalopram—Dysgeusia—Capecitabine—esophageal cancer	0.000277	0.000787	CcSEcCtD
Citalopram—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000276	0.000784	CcSEcCtD
Citalopram—Back pain—Capecitabine—esophageal cancer	0.000274	0.000778	CcSEcCtD
Citalopram—Decreased appetite—Cisplatin—esophageal cancer	0.000273	0.000774	CcSEcCtD
Citalopram—Muscle spasms—Capecitabine—esophageal cancer	0.000272	0.000773	CcSEcCtD
Citalopram—Pneumonia—Methotrexate—esophageal cancer	0.000271	0.00077	CcSEcCtD
Citalopram—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000271	0.000769	CcSEcCtD
Citalopram—Infestation—Methotrexate—esophageal cancer	0.00027	0.000766	CcSEcCtD
Citalopram—Infestation NOS—Methotrexate—esophageal cancer	0.00027	0.000766	CcSEcCtD
Citalopram—Depression—Methotrexate—esophageal cancer	0.000269	0.000764	CcSEcCtD
Citalopram—Pain—Cisplatin—esophageal cancer	0.000268	0.000761	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000267	0.000759	CcSEcCtD
Citalopram—Vision blurred—Capecitabine—esophageal cancer	0.000267	0.000758	CcSEcCtD
Citalopram—Tremor—Capecitabine—esophageal cancer	0.000265	0.000753	CcSEcCtD
Citalopram—Stomatitis—Methotrexate—esophageal cancer	0.000263	0.000747	CcSEcCtD
Citalopram—Ill-defined disorder—Capecitabine—esophageal cancer	0.000263	0.000746	CcSEcCtD
Citalopram—Conjunctivitis—Methotrexate—esophageal cancer	0.000262	0.000745	CcSEcCtD
Citalopram—Anaemia—Capecitabine—esophageal cancer	0.000262	0.000743	CcSEcCtD
Citalopram—Sweating—Methotrexate—esophageal cancer	0.000259	0.000734	CcSEcCtD
Citalopram—Feeling abnormal—Cisplatin—esophageal cancer	0.000258	0.000734	CcSEcCtD
Citalopram—Haematuria—Methotrexate—esophageal cancer	0.000257	0.00073	CcSEcCtD
Citalopram—Malaise—Capecitabine—esophageal cancer	0.000255	0.000725	CcSEcCtD
Citalopram—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000255	0.000724	CcSEcCtD
Citalopram—Epistaxis—Methotrexate—esophageal cancer	0.000254	0.000722	CcSEcCtD
Citalopram—Vertigo—Capecitabine—esophageal cancer	0.000254	0.000722	CcSEcCtD
Citalopram—Syncope—Capecitabine—esophageal cancer	0.000254	0.000721	CcSEcCtD
Citalopram—Leukopenia—Capecitabine—esophageal cancer	0.000254	0.00072	CcSEcCtD
Citalopram—Agranulocytosis—Methotrexate—esophageal cancer	0.000252	0.000715	CcSEcCtD
Citalopram—Palpitations—Capecitabine—esophageal cancer	0.00025	0.000711	CcSEcCtD
Citalopram—Loss of consciousness—Capecitabine—esophageal cancer	0.000249	0.000707	CcSEcCtD
Citalopram—Body temperature increased—Cisplatin—esophageal cancer	0.000248	0.000704	CcSEcCtD
Citalopram—Cough—Capecitabine—esophageal cancer	0.000247	0.000702	CcSEcCtD
Citalopram—Hypertension—Capecitabine—esophageal cancer	0.000245	0.000694	CcSEcCtD
Citalopram—Haemoglobin—Methotrexate—esophageal cancer	0.000243	0.000691	CcSEcCtD
Citalopram—Haemorrhage—Methotrexate—esophageal cancer	0.000242	0.000688	CcSEcCtD
Citalopram—Hepatitis—Methotrexate—esophageal cancer	0.000242	0.000688	CcSEcCtD
Citalopram—Chest pain—Capecitabine—esophageal cancer	0.000241	0.000685	CcSEcCtD
Citalopram—Myalgia—Capecitabine—esophageal cancer	0.000241	0.000685	CcSEcCtD
Citalopram—Arthralgia—Capecitabine—esophageal cancer	0.000241	0.000685	CcSEcCtD
Citalopram—Pharyngitis—Methotrexate—esophageal cancer	0.00024	0.000682	CcSEcCtD
Citalopram—Anxiety—Capecitabine—esophageal cancer	0.00024	0.000682	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000239	0.00068	CcSEcCtD
Citalopram—Urinary tract disorder—Methotrexate—esophageal cancer	0.000239	0.000679	CcSEcCtD
Citalopram—Discomfort—Capecitabine—esophageal cancer	0.000238	0.000676	CcSEcCtD
Citalopram—Urethral disorder—Methotrexate—esophageal cancer	0.000237	0.000674	CcSEcCtD
Citalopram—Dry mouth—Capecitabine—esophageal cancer	0.000236	0.00067	CcSEcCtD
Citalopram—Visual impairment—Methotrexate—esophageal cancer	0.000233	0.000663	CcSEcCtD
Citalopram—Confusional state—Capecitabine—esophageal cancer	0.000233	0.000662	CcSEcCtD
Citalopram—Oedema—Capecitabine—esophageal cancer	0.000231	0.000656	CcSEcCtD
Citalopram—Hypersensitivity—Cisplatin—esophageal cancer	0.000231	0.000656	CcSEcCtD
Citalopram—Infection—Capecitabine—esophageal cancer	0.00023	0.000652	CcSEcCtD
Citalopram—Erythema multiforme—Methotrexate—esophageal cancer	0.000229	0.00065	CcSEcCtD
Citalopram—Shock—Capecitabine—esophageal cancer	0.000227	0.000646	CcSEcCtD
Citalopram—Nervous system disorder—Capecitabine—esophageal cancer	0.000227	0.000644	CcSEcCtD
Citalopram—Eye disorder—Methotrexate—esophageal cancer	0.000226	0.000643	CcSEcCtD
Citalopram—Thrombocytopenia—Capecitabine—esophageal cancer	0.000226	0.000643	CcSEcCtD
Citalopram—Tinnitus—Methotrexate—esophageal cancer	0.000226	0.000641	CcSEcCtD
Citalopram—Tachycardia—Capecitabine—esophageal cancer	0.000226	0.00064	CcSEcCtD
Citalopram—Asthenia—Cisplatin—esophageal cancer	0.000225	0.000639	CcSEcCtD
Citalopram—Cardiac disorder—Methotrexate—esophageal cancer	0.000225	0.000638	CcSEcCtD
Citalopram—Skin disorder—Capecitabine—esophageal cancer	0.000225	0.000637	CcSEcCtD
Citalopram—Hyperhidrosis—Capecitabine—esophageal cancer	0.000223	0.000634	CcSEcCtD
Citalopram—Anorexia—Capecitabine—esophageal cancer	0.00022	0.000626	CcSEcCtD
Citalopram—Angiopathy—Methotrexate—esophageal cancer	0.00022	0.000624	CcSEcCtD
Citalopram—Immune system disorder—Methotrexate—esophageal cancer	0.000219	0.000621	CcSEcCtD
Citalopram—Mediastinal disorder—Methotrexate—esophageal cancer	0.000218	0.00062	CcSEcCtD
Citalopram—Chills—Methotrexate—esophageal cancer	0.000217	0.000617	CcSEcCtD
Citalopram—Hypotension—Capecitabine—esophageal cancer	0.000216	0.000613	CcSEcCtD
Citalopram—Diarrhoea—Cisplatin—esophageal cancer	0.000215	0.000609	CcSEcCtD
Citalopram—Alopecia—Methotrexate—esophageal cancer	0.000214	0.000608	CcSEcCtD
Citalopram—Mental disorder—Methotrexate—esophageal cancer	0.000212	0.000602	CcSEcCtD
Citalopram—Malnutrition—Methotrexate—esophageal cancer	0.000211	0.000599	CcSEcCtD
Citalopram—Erythema—Methotrexate—esophageal cancer	0.000211	0.000599	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000211	0.000598	CcSEcCtD
Citalopram—Insomnia—Capecitabine—esophageal cancer	0.000209	0.000594	CcSEcCtD
Citalopram—Paraesthesia—Capecitabine—esophageal cancer	0.000208	0.000589	CcSEcCtD
Citalopram—Dysgeusia—Methotrexate—esophageal cancer	0.000206	0.000586	CcSEcCtD
Citalopram—Dyspnoea—Capecitabine—esophageal cancer	0.000206	0.000585	CcSEcCtD
Citalopram—Back pain—Methotrexate—esophageal cancer	0.000204	0.000579	CcSEcCtD
Citalopram—Dyspepsia—Capecitabine—esophageal cancer	0.000203	0.000578	CcSEcCtD
Citalopram—Decreased appetite—Capecitabine—esophageal cancer	0.000201	0.00057	CcSEcCtD
Citalopram—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0002	0.000567	CcSEcCtD
Citalopram—Vomiting—Cisplatin—esophageal cancer	0.000199	0.000566	CcSEcCtD
Citalopram—Fatigue—Capecitabine—esophageal cancer	0.000199	0.000566	CcSEcCtD
Citalopram—Vision blurred—Methotrexate—esophageal cancer	0.000199	0.000564	CcSEcCtD
Citalopram—Rash—Cisplatin—esophageal cancer	0.000198	0.000561	CcSEcCtD
Citalopram—Pain—Capecitabine—esophageal cancer	0.000198	0.000561	CcSEcCtD
Citalopram—Constipation—Capecitabine—esophageal cancer	0.000198	0.000561	CcSEcCtD
Citalopram—Dermatitis—Cisplatin—esophageal cancer	0.000198	0.000561	CcSEcCtD
Citalopram—Ill-defined disorder—Methotrexate—esophageal cancer	0.000196	0.000555	CcSEcCtD
Citalopram—Anaemia—Methotrexate—esophageal cancer	0.000195	0.000553	CcSEcCtD
Citalopram—Feeling abnormal—Capecitabine—esophageal cancer	0.00019	0.000541	CcSEcCtD
Citalopram—Malaise—Methotrexate—esophageal cancer	0.00019	0.00054	CcSEcCtD
Citalopram—Vertigo—Methotrexate—esophageal cancer	0.000189	0.000538	CcSEcCtD
Citalopram—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000189	0.000537	CcSEcCtD
Citalopram—Leukopenia—Methotrexate—esophageal cancer	0.000189	0.000536	CcSEcCtD
Citalopram—Nausea—Cisplatin—esophageal cancer	0.000186	0.000529	CcSEcCtD
Citalopram—Cough—Methotrexate—esophageal cancer	0.000184	0.000522	CcSEcCtD
Citalopram—Urticaria—Capecitabine—esophageal cancer	0.000184	0.000521	CcSEcCtD
Citalopram—Body temperature increased—Capecitabine—esophageal cancer	0.000183	0.000519	CcSEcCtD
Citalopram—Abdominal pain—Capecitabine—esophageal cancer	0.000183	0.000519	CcSEcCtD
Citalopram—Convulsion—Methotrexate—esophageal cancer	0.000183	0.000519	CcSEcCtD
Citalopram—Myalgia—Methotrexate—esophageal cancer	0.000179	0.00051	CcSEcCtD
Citalopram—Arthralgia—Methotrexate—esophageal cancer	0.000179	0.00051	CcSEcCtD
Citalopram—Chest pain—Methotrexate—esophageal cancer	0.000179	0.00051	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000178	0.000506	CcSEcCtD
Citalopram—Discomfort—Methotrexate—esophageal cancer	0.000177	0.000504	CcSEcCtD
Citalopram—Confusional state—Methotrexate—esophageal cancer	0.000173	0.000493	CcSEcCtD
Citalopram—Anaphylactic shock—Methotrexate—esophageal cancer	0.000172	0.000489	CcSEcCtD
Citalopram—Infection—Methotrexate—esophageal cancer	0.000171	0.000485	CcSEcCtD
Citalopram—Hypersensitivity—Capecitabine—esophageal cancer	0.00017	0.000484	CcSEcCtD
Citalopram—Nervous system disorder—Methotrexate—esophageal cancer	0.000169	0.000479	CcSEcCtD
Citalopram—Thrombocytopenia—Methotrexate—esophageal cancer	0.000168	0.000478	CcSEcCtD
Citalopram—Skin disorder—Methotrexate—esophageal cancer	0.000167	0.000475	CcSEcCtD
Citalopram—Hyperhidrosis—Methotrexate—esophageal cancer	0.000166	0.000472	CcSEcCtD
Citalopram—Asthenia—Capecitabine—esophageal cancer	0.000166	0.000471	CcSEcCtD
Citalopram—Anorexia—Methotrexate—esophageal cancer	0.000164	0.000466	CcSEcCtD
Citalopram—Pruritus—Capecitabine—esophageal cancer	0.000164	0.000464	CcSEcCtD
Citalopram—Hypotension—Methotrexate—esophageal cancer	0.000161	0.000456	CcSEcCtD
Citalopram—Diarrhoea—Capecitabine—esophageal cancer	0.000158	0.000449	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000157	0.000445	CcSEcCtD
Citalopram—Insomnia—Methotrexate—esophageal cancer	0.000156	0.000442	CcSEcCtD
Citalopram—Paraesthesia—Methotrexate—esophageal cancer	0.000155	0.000439	CcSEcCtD
Citalopram—Dyspnoea—Methotrexate—esophageal cancer	0.000153	0.000436	CcSEcCtD
Citalopram—Somnolence—Methotrexate—esophageal cancer	0.000153	0.000434	CcSEcCtD
Citalopram—Dizziness—Capecitabine—esophageal cancer	0.000153	0.000434	CcSEcCtD
Citalopram—Dyspepsia—Methotrexate—esophageal cancer	0.000151	0.00043	CcSEcCtD
Citalopram—Decreased appetite—Methotrexate—esophageal cancer	0.00015	0.000425	CcSEcCtD
Citalopram—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000149	0.000422	CcSEcCtD
Citalopram—Fatigue—Methotrexate—esophageal cancer	0.000148	0.000421	CcSEcCtD
Citalopram—Pain—Methotrexate—esophageal cancer	0.000147	0.000418	CcSEcCtD
Citalopram—Vomiting—Capecitabine—esophageal cancer	0.000147	0.000417	CcSEcCtD
Citalopram—Rash—Capecitabine—esophageal cancer	0.000146	0.000414	CcSEcCtD
Citalopram—Dermatitis—Capecitabine—esophageal cancer	0.000146	0.000413	CcSEcCtD
Citalopram—Headache—Capecitabine—esophageal cancer	0.000145	0.000411	CcSEcCtD
Citalopram—Feeling abnormal—Methotrexate—esophageal cancer	0.000142	0.000403	CcSEcCtD
Citalopram—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000141	0.000399	CcSEcCtD
Citalopram—Nausea—Capecitabine—esophageal cancer	0.000137	0.00039	CcSEcCtD
Citalopram—Urticaria—Methotrexate—esophageal cancer	0.000137	0.000388	CcSEcCtD
Citalopram—Body temperature increased—Methotrexate—esophageal cancer	0.000136	0.000386	CcSEcCtD
Citalopram—Abdominal pain—Methotrexate—esophageal cancer	0.000136	0.000386	CcSEcCtD
Citalopram—Hypersensitivity—Methotrexate—esophageal cancer	0.000127	0.00036	CcSEcCtD
Citalopram—Asthenia—Methotrexate—esophageal cancer	0.000123	0.000351	CcSEcCtD
Citalopram—Pruritus—Methotrexate—esophageal cancer	0.000122	0.000346	CcSEcCtD
Citalopram—Diarrhoea—Methotrexate—esophageal cancer	0.000118	0.000334	CcSEcCtD
Citalopram—Dizziness—Methotrexate—esophageal cancer	0.000114	0.000323	CcSEcCtD
Citalopram—Vomiting—Methotrexate—esophageal cancer	0.000109	0.000311	CcSEcCtD
Citalopram—Rash—Methotrexate—esophageal cancer	0.000108	0.000308	CcSEcCtD
Citalopram—Dermatitis—Methotrexate—esophageal cancer	0.000108	0.000308	CcSEcCtD
Citalopram—Headache—Methotrexate—esophageal cancer	0.000108	0.000306	CcSEcCtD
Citalopram—Nausea—Methotrexate—esophageal cancer	0.000102	0.00029	CcSEcCtD
Citalopram—CYP2C19—Metabolism—ALDOB—esophageal cancer	2.92e-05	0.000138	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PSME1—esophageal cancer	2.89e-05	0.000137	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PSME2—esophageal cancer	2.89e-05	0.000137	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ENO1—esophageal cancer	2.87e-05	0.000136	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS1—esophageal cancer	2.87e-05	0.000136	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALDOB—esophageal cancer	2.85e-05	0.000135	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CA1—esophageal cancer	2.85e-05	0.000135	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.85e-05	0.000135	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PSME2—esophageal cancer	2.83e-05	0.000134	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PSME1—esophageal cancer	2.83e-05	0.000134	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PSME2—esophageal cancer	2.83e-05	0.000134	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PSME1—esophageal cancer	2.83e-05	0.000134	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PSME1—esophageal cancer	2.82e-05	0.000133	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PSME2—esophageal cancer	2.82e-05	0.000133	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GAPDH—esophageal cancer	2.82e-05	0.000133	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ANXA1—esophageal cancer	2.81e-05	0.000133	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—TPI1—esophageal cancer	2.81e-05	0.000133	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTO1—esophageal cancer	2.81e-05	0.000133	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ANXA1—esophageal cancer	2.8e-05	0.000133	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CRABP1—esophageal cancer	2.79e-05	0.000132	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	2.77e-05	0.000131	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	2.77e-05	0.000131	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NOTCH2—esophageal cancer	2.76e-05	0.000131	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	2.76e-05	0.000131	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ADH1B—esophageal cancer	2.75e-05	0.00013	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GAPDH—esophageal cancer	2.75e-05	0.00013	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.74e-05	0.00013	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SST—esophageal cancer	2.74e-05	0.000129	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SST—esophageal cancer	2.73e-05	0.000129	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CRABP1—esophageal cancer	2.72e-05	0.000129	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.69e-05	0.000127	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SST—esophageal cancer	2.69e-05	0.000127	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOTCH3—esophageal cancer	2.67e-05	0.000126	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—GHRL—esophageal cancer	2.67e-05	0.000126	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—GHRL—esophageal cancer	2.66e-05	0.000126	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOTCH3—esophageal cancer	2.66e-05	0.000126	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GNG7—esophageal cancer	2.65e-05	0.000125	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.65e-05	0.000125	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMP—esophageal cancer	2.63e-05	0.000124	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FBXW7—esophageal cancer	2.62e-05	0.000124	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	2.62e-05	0.000124	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	2.62e-05	0.000124	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FBXW7—esophageal cancer	2.62e-05	0.000124	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CA2—esophageal cancer	2.6e-05	0.000123	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GNG7—esophageal cancer	2.59e-05	0.000122	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.59e-05	0.000122	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	2.58e-05	0.000122	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CRABP1—esophageal cancer	2.57e-05	0.000121	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP26A1—esophageal cancer	2.56e-05	0.000121	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP1B1—esophageal cancer	2.49e-05	0.000118	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALOX15—esophageal cancer	2.49e-05	0.000118	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.49e-05	0.000118	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	2.45e-05	0.000116	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP1B1—esophageal cancer	2.44e-05	0.000115	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GNG7—esophageal cancer	2.44e-05	0.000115	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALDH2—esophageal cancer	2.43e-05	0.000115	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.42e-05	0.000114	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ADH7—esophageal cancer	2.42e-05	0.000114	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOTCH2—esophageal cancer	2.39e-05	0.000113	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	2.38e-05	0.000113	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TPI1—esophageal cancer	2.38e-05	0.000112	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTO1—esophageal cancer	2.38e-05	0.000112	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTT1—esophageal cancer	2.37e-05	0.000112	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	2.35e-05	0.000111	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP19A1—esophageal cancer	2.34e-05	0.000111	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.34e-05	0.000111	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.33e-05	0.00011	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	2.32e-05	0.00011	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTT1—esophageal cancer	2.31e-05	0.000109	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP19A1—esophageal cancer	2.3e-05	0.000109	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.29e-05	0.000108	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.28e-05	0.000108	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALDOB—esophageal cancer	2.28e-05	0.000108	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ENO1—esophageal cancer	2.22e-05	0.000105	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS1—esophageal cancer	2.22e-05	0.000105	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GAPDH—esophageal cancer	2.19e-05	0.000104	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PSME2—esophageal cancer	2.18e-05	0.000103	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PSME1—esophageal cancer	2.18e-05	0.000103	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.18e-05	0.000103	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CRABP1—esophageal cancer	2.17e-05	0.000103	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ENO1—esophageal cancer	2.16e-05	0.000102	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS1—esophageal cancer	2.16e-05	0.000102	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.16e-05	0.000102	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.15e-05	0.000102	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—HMOX1—esophageal cancer	2.14e-05	0.000101	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PSME1—esophageal cancer	2.13e-05	0.000101	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PSME2—esophageal cancer	2.13e-05	0.000101	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.12e-05	0.0001	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	2.12e-05	0.0001	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	2.12e-05	0.0001	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—HMOX1—esophageal cancer	2.1e-05	9.91e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	2.08e-05	9.85e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GNG7—esophageal cancer	2.07e-05	9.78e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ABCB1—esophageal cancer	2.05e-05	9.71e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ENO1—esophageal cancer	2.04e-05	9.64e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.04e-05	9.64e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMP—esophageal cancer	2.03e-05	9.59e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ABCB1—esophageal cancer	2.01e-05	9.51e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SMAD4—esophageal cancer	2.01e-05	9.5e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PSME2—esophageal cancer	2.01e-05	9.5e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PSME1—esophageal cancer	2.01e-05	9.5e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	2e-05	9.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.97e-05	9.33e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	1.97e-05	9.32e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.94e-05	9.16e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.92e-05	9.09e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.91e-05	9.02e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	1.9e-05	8.97e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.88e-05	8.91e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.84e-05	8.71e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.84e-05	8.7e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.83e-05	8.67e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TPI1—esophageal cancer	1.83e-05	8.67e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.82e-05	8.61e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.81e-05	8.58e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KDR—esophageal cancer	1.81e-05	8.58e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.77e-05	8.38e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.76e-05	8.32e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.73e-05	8.2e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.73e-05	8.18e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.73e-05	8.17e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ENO1—esophageal cancer	1.73e-05	8.17e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	1.71e-05	8.08e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PSME1—esophageal cancer	1.7e-05	8.05e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PSME2—esophageal cancer	1.7e-05	8.05e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.69e-05	8e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.68e-05	7.93e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HIF1A—esophageal cancer	1.64e-05	7.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	1.64e-05	7.75e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.63e-05	7.71e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.62e-05	7.64e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	1.61e-05	7.63e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GNG7—esophageal cancer	1.6e-05	7.55e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.59e-05	7.5e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—HMOX1—esophageal cancer	1.58e-05	7.46e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KDR—esophageal cancer	1.57e-05	7.43e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KDR—esophageal cancer	1.57e-05	7.41e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.55e-05	7.34e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	1.55e-05	7.33e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KDR—esophageal cancer	1.54e-05	7.29e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	1.52e-05	7.2e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.5e-05	7.07e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.49e-05	7.03e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.49e-05	7.03e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	1.48e-05	7e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	1.48e-05	6.98e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.47e-05	6.94e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.46e-05	6.88e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	1.45e-05	6.87e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.43e-05	6.75e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.42e-05	6.73e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.41e-05	6.65e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.39e-05	6.56e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.38e-05	6.53e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.37e-05	6.49e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CREBBP—esophageal cancer	1.34e-05	6.36e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CREBBP—esophageal cancer	1.34e-05	6.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	1.34e-05	6.33e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ENO1—esophageal cancer	1.33e-05	6.3e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.33e-05	6.3e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.32e-05	6.25e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—esophageal cancer	1.32e-05	6.24e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	1.32e-05	6.23e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	1.32e-05	6.22e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PSME2—esophageal cancer	1.31e-05	6.21e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PSME1—esophageal cancer	1.31e-05	6.21e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.3e-05	6.14e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	1.29e-05	6.12e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.26e-05	5.96e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.26e-05	5.96e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.26e-05	5.94e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.24e-05	5.85e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.24e-05	5.84e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NOS3—esophageal cancer	1.23e-05	5.81e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.21e-05	5.72e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NOS3—esophageal cancer	1.2e-05	5.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.2e-05	5.68e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOS3—esophageal cancer	1.2e-05	5.67e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.18e-05	5.58e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.17e-05	5.55e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.15e-05	5.42e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.15e-05	5.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	1.14e-05	5.4e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.13e-05	5.36e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1.12e-05	5.32e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—esophageal cancer	1.12e-05	5.31e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.12e-05	5.31e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	1.12e-05	5.3e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.11e-05	5.24e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	1.1e-05	5.22e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—esophageal cancer	1.1e-05	5.21e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.07e-05	5.04e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.06e-05	4.99e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.04e-05	4.9e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CREBBP—esophageal cancer	1.01e-05	4.79e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—esophageal cancer	9.93e-06	4.7e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—esophageal cancer	9.9e-06	4.68e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	9.75e-06	4.61e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HMOX1—esophageal cancer	9.72e-06	4.6e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	9.61e-06	4.54e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	9.58e-06	4.53e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CREBBP—esophageal cancer	9.54e-06	4.51e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	9.43e-06	4.46e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—EP300—esophageal cancer	9.35e-06	4.42e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCB1—esophageal cancer	9.33e-06	4.41e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NOS3—esophageal cancer	9.29e-06	4.39e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—esophageal cancer	9.2e-06	4.35e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—EP300—esophageal cancer	9.16e-06	4.33e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EP300—esophageal cancer	9.14e-06	4.32e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.14e-06	4.32e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EP300—esophageal cancer	9.12e-06	4.31e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NOS3—esophageal cancer	9.06e-06	4.29e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—esophageal cancer	9e-06	4.25e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EP300—esophageal cancer	8.97e-06	4.24e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NOS3—esophageal cancer	8.54e-06	4.04e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—esophageal cancer	8.49e-06	4.02e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—esophageal cancer	8.29e-06	3.92e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CREBBP—esophageal cancer	8.08e-06	3.82e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—esophageal cancer	7.97e-06	3.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—esophageal cancer	7.94e-06	3.76e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—esophageal cancer	7.82e-06	3.7e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.81e-06	3.69e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	7.81e-06	3.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—esophageal cancer	7.79e-06	3.69e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—esophageal cancer	7.77e-06	3.67e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	7.65e-06	3.62e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—esophageal cancer	7.55e-06	3.57e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NOS3—esophageal cancer	7.24e-06	3.42e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—EP300—esophageal cancer	7.06e-06	3.34e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—esophageal cancer	6.92e-06	3.27e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—EP300—esophageal cancer	6.9e-06	3.26e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—esophageal cancer	6.77e-06	3.2e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	6.76e-06	3.2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	6.74e-06	3.19e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	6.64e-06	3.14e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—esophageal cancer	6.62e-06	3.13e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—esophageal cancer	6.54e-06	3.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—esophageal cancer	6.52e-06	3.08e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—EP300—esophageal cancer	6.5e-06	3.07e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—esophageal cancer	6.42e-06	3.04e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CREBBP—esophageal cancer	6.24e-06	2.95e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NOS3—esophageal cancer	5.58e-06	2.64e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—EP300—esophageal cancer	5.5e-06	2.6e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—esophageal cancer	5.23e-06	2.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—esophageal cancer	5.11e-06	2.41e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—esophageal cancer	5.1e-06	2.41e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.81e-06	2.27e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—EP300—esophageal cancer	4.25e-06	2.01e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—esophageal cancer	4.07e-06	1.93e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.14e-06	1.49e-05	CbGpPWpGaD
